CyberArk Named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management
CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is positioned as a Leader for the sixth consecutive time and is positioned furthest in Completeness of Vision, which evaluates vendors on offering (product) strategy, innovation and market understanding among other evaluation criteria.
With 93% of organizations suffering two or more identity-related breaches in the last 12 months, managing and securing identities has become a critical requirement. The CyberArk Identity Security Platform enables organizations to secure the entire spectrum of identities, including workforce, IT, developer and machine, supporting modern access use cases such as the need to enforce Zero Standing Privileges in public cloud environments. A core component of the platform is CyberArk’s privileged access management (PAM) capabilities, which allow customers to apply flexible privilege controls to help prevent malicious account, credential and secrets access throughout the entire enterprise infrastructure.
“We are incredibly proud to once again be named a Leader by Gartner. CyberArk delivers identity security programs for a multi-cloud world. We feel that our position as a Leader in this year’s report, for the sixth consecutive time, is a testament to our commitment to ongoing innovation and customer success,” said Matt Cohen, CEO, CyberArk. “Identity security is no longer just about human identities. As identities – especially machine identities - proliferate, driven by new hybrid and multi-cloud environments, an effective identity security strategy must secure them all with the right level of privilege controls. CyberArk’s advanced PAM, secrets management and endpoint privilege security capabilities are key to empowering our customers to secure every identity and defend against cyberattacks.”
CyberArk aims to deliver the industry’s most comprehensive identity security platform, including:
- Outstanding Customer Experience: CyberArk is committed to a customer-first approach, ensuring that all identities are secured with the right level of privilege controls, while putting the customer at the center of all it does. Its unified, SaaS-based platform notably simplifies and improves the administrator and end user experience to reduce cost and complexity, helping organizations accelerate their migration to the cloud with consistent identity security controls in place.
- PAM Programs for a Multi-Cloud World: The CyberArk Identity Security Platform provides best-in-class, end-to-end PAM capabilities. CyberArk centrally and natively secures both shared and federated privileged access for IT and cloud ops teams supporting digital initiatives. By applying intelligent privilege controls within native tooling, CyberArk helps PAM programs scale across all environments – from long-lived systems in on-premises data centers to elastic cloud workloads, public cloud services and SaaS apps.
- Unified, Cross-Platform Innovation, Powered by AI: CyberArk recently introduced new capabilities for securing every identity, further extending PAM controls to all identity types, including workforce identities. Offerings now include support for secure standing access and zero standing privileges, with the ability to isolate and audit privileged sessions. In addition, CyberArk Endpoint Privilege Manager now offers strong end-to-end passwordless authentication when signing into endpoints and elevating application controls. CyberArk’s unified portal means that the end user experience is enhanced with one-click, native access to enterprise resources, while intelligent privilege controls protect the user. Earlier this year, CyberArk also announced CORA AI™, which will allow organizations to analyze anomalies and apply next-level identity threat detection and response actions, reducing reaction times from hours to minutes.
- World-Leading Partner Support and Technology Ecosystem: CyberArk aims to make it easier for partners to develop deep identity security practices and measurably reduce cybersecurity risk for customers. CyberArk invests heavily in its Channel Partner Program, with the launch of a new self-service portal for partners – as well as the CyberArk MSP Console - and new certifications underscoring its commitment to value creation for both joint customers and partners. CyberArk’s global ecosystem brings together more than 1,300 system integrators, managed service providers, strategic outsourcers, advisories, solution providers, distributors and marketplaces. Alongside this partner network, the CyberArk C3 technology alliance allows customers to make the most of their existing technology investments, featuring more than 200 certified integrations from providers of enterprise software, infrastructure and security solutions.
To download a complimentary copy of the 2024 Gartner Magic Quadrant for Privileged Access Management visit: https://www.cyberark.com/gartner-2024-mq-pam
1 – Gartner® Magic Quadrant™ for Privileged Access Management, by Abhyuday Data, Michael Kelley, Nayara Sangiorgio, Felix Gaehtgens, Paul Mezzera, 9 September 2024
Gartner Disclaimers
GARTNER is a registered trademarks and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About CyberArk
CyberArk (NASDAQ: CYBR) is the global leader in identity security. Centered on intelligent privilege controls, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud environments and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com, read the CyberArk blogs or follow on LinkedIn, X, Facebook or YouTube.
Copyright © 2024 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910351926/en/
Contacts
Investor Relations:
Srinivas Anantha, CFA
CyberArk
617-558-2132
ir@cyberark.com
Media:
Nick Bowman
CyberArk
+44 (0) 7841 673378
press@cyberark.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom